We are live on ! Find out more
TPTX

Turning Point Therapeutics, Inc. Common Stock
TPTX

Delisted

TPTX was delisted on the 16th of August, 2022.

Back to rankings

0 hedge funds and large institutions have $0 invested in Turning Point Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 208 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 208 → 0 (-208)

100% less funds holding in top 10

Funds holding in top 10: 10 → 0 (-10)

100% less capital invested

Capital invested by funds: $3.06B → $0 (-$3.06B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 208

Holders
–
Holders Change
-208
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-10
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
208
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$313M
2
BlackRock
BlackRock
New York
-$285M
3
CAM
Cormorant Asset Management
Massachusetts
-$187M
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$144M
5
State Street
State Street
Massachusetts
-$124M
Name Holding Trade Value Shares
Change 		Change in
Stake
AB
151
Amalgamated Bank
New York
– -$449K -5,968 Closed
Envestnet Asset Management
152
Envestnet Asset Management
Illinois
– -$448K -5,954 Closed
Public Employees Retirement Association of Colorado
153
Public Employees Retirement Association of Colorado
Colorado
– -$442K -5,880 Closed
PCM
154
PenderFund Capital Management
British Columbia, Canada
– -$502K -5,180 Closed
SG
155
Stonnington Group
California
– -$383K -5,100 Closed
TI
156
Telemetry Investments
New York
– -$376K -5,000 Closed
AAM
157
Advisors Asset Management
Colorado
– -$374K -4,964 Closed
TRCT
158
Tower Research Capital (TRC)
New York
– -$372K -4,941 Closed
SCS
159
Syquant Capital SAS
France
– -$339K -4,500 Closed
QC
160
QCM Cayman
Texas
– -$333K -4,428 Closed
EFM
161
E Fund Management
China
– -$321K -4,268 Closed
Los Angeles Capital Management
162
Los Angeles Capital Management
California
– -$321K -4,260 Closed
Verition Fund Management
163
Verition Fund Management
Connecticut
– -$296K -3,927 Closed
SEI Investments
164
SEI Investments
Pennsylvania
– -$282K -3,752 Closed
AIP
165
Ameritas Investment Partners
Nebraska
– -$258K -3,433 Closed
Mackenzie Financial
166
Mackenzie Financial
Ontario, Canada
– -$241K -3,209 Closed
BCI
167
Brinker Capital Investments
Pennsylvania
– -$238K -3,167 Closed
ECM
168
ExodusPoint Capital Management
New York
– -$229K -3,047 Closed
DC
169
Diametric Capital
Massachusetts
– -$226K -3,000 Closed
Vontobel Holding
170
Vontobel Holding
Switzerland
– -$226K -3,000 Closed
PM
171
Parametrica Management
Hong Kong
– -$223K -2,970 Closed
MLICM
172
Metropolitan Life Insurance Company (MetLife)
New York
– -$208K -2,761 Closed
Canada Life
173
Canada Life
Manitoba, Canada
– -$192K -2,550 Closed
FLC
174
Fifth Lane Capital
Texas
– -$188K -2,500 Closed
Amundi
175
Amundi
France
– -$187K -2,491 Closed
5 6
7
8 9

TPTX Hedge Fund Activity: Q3 2022 in Review

0 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Turning Point Therapeutics, Inc. Common Stock (TPTX) for Q3 2022, worth a combined $0 — down 100% from $3.06B a quarter earlier.

Sellers outnumbered buyers: 208 funds closed out of TPTX and 0 opened new positions — a net loss of 208 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $313M sold.

  • 0 institutional investors held Turning Point Therapeutics, Inc. Common Stock (TPTX) as of Q3 2022, down from 208 in Q2 2022.
  • Funds reported $0 of Turning Point Therapeutics, Inc. Common Stock stock for Q3 2022, down 100% quarter-over-quarter.
  • 0 funds opened new Turning Point Therapeutics, Inc. Common Stock positions in Q3 2022 and 208 closed out, a net change of -208 holders.
  • The largest Turning Point Therapeutics, Inc. Common Stock seller in Q3 2022 was Vanguard Group, an estimated $313M sold.

Based on aggregated 13F filings for Q3 2022.